⌘K
t
Beximco Pharmaceuticals PLC announced its unaudited financial results for the third quarter and nine months ended 31 March 2025 on 24 June 2026. For the nine-month period, net revenue increased 10.8% to £235.0m, and profit after tax rose 20.3% to £33.8m. During the third quarter, the company reported a 14.8% increase in net revenue to £80.9m and a 26.3% increase in profit after tax to £11.1m.
| Date | 24 Jun 2026 |
| Time | 07:01:00 |
| Category | Results |
| ID | 4581J |
24 June 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Q3 Financial Results 2024-25
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the third quarter and nine months ended 31 March 2025.
Financial Highlights (Consolidated)
Nine months ended 31 March 2025
· Net revenue increased 10.8% to Bangladesh Taka ("BDT") 36,622.0m / £235.0m (2023-24: BDT 33,050.9m / £239.1m)
o Domestic sales increased 8.5% to BDT 33,617.7m / £215.7m (2023-24: BDT 30,987.0m / £224.1m)
o Export sales increased 45.6% to BDT 3,004.3m / £19.3m (2023-24: BDT 2,063.9m / £14.9m)
· Profit after tax increased 20.3% to BDT 5,261.0m / £33.8m (2023-24: BDT 4,374.7m / £31.6m)
Third-quarter ended 31 March 2025
· Net revenue increased 14.8% to BDT 12,608.6m / £80.9m (2023-24: BDT 10,987.3m / £79.5m)
· Profit after tax increased 26.3% to BDT 1,726.0m / £11.1m (2023-24: BDT 1,366.6m / £9.9m)
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.
(Exchange rates of £1=Taka 155.8649 for 31 March 2025 and £1=Taka 138.2585 for 31 March 2024 have been used in this announcement.)
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at March 31, 2025
|
|
March 31, 2025 |
|
Taka '000
June 30, 2024 |
|
ASSETS |
|
|
|
|
|
|
|
|
|
Non-current assets |
49,405,558 |
|
48,526,439 |
|
Property, plant and equipment |
43,383,769 |
|
42,487,711 |
|
Right-of-use assets |
582,493 |
|
561,597 |
|
Intangible assets |
4,691,106 |
|
4,720,697 |
|
Deferred tax asset |
52,646 |
|
60,891 |
|
Goodwill |
674,570 |
|
674,570 |
|
Other investments |
20,974 |
|
20,973 |
|
|
|
|
|
|
Current assets |
25,449,285 |
|
20,817,584 |
|
Inventories |
14,100,238 |
|
12,118,129 |
|
Spares and supplies |
844,783 |
|
896,665 |
|
Trade and other receivables |
4,439,493 |
|
3,767,319 |
|
Loans, advances, deposits and prepayments |
2,942,187 |
|
2,686,195 |
|
Advance income tax |
339,484 |
|
295,170 |
|
Short term investment |
900,000 |
|
200,000 |
|
Cash and cash equivalents |
1,883,100 |
|
854,106 |
|
|
|
|
|
|
TOTAL ASSETS |
74,854,843 |
|
69,344,023 |
|
|
|
|
|
|
SHAREHOLDERS' EQUITY AND LIABILITIES |
|
|
|
|
Equity attributable to the owners of the company |
51,398,004 |
|
47,949,965 |
|
Share capital |
4,461,121 |
|
4,461,121 |
|
Share premium |
5,269,475 |
|
5,269,475 |
|
Excess of issue price over face value of GDRs |
1,689,637 |
|
1,689,637 |
|
Capital reserve on merger |
294,951 |
|
294,951 |
|
Revaluation surplus |
1,134,729 |
|
1,137,306 |
|
Unrealized gain/(loss) |
18,149 |
|
18,148 |
|
Retained earnings |
38,529,942 |
|
35,079,327 |
|
|
|
|
|
|
Non-controlling interest |
3,948,520 |
|
3,952,938 |
|
|
|
|
|
|
TOTAL EQUITY |
55,346,524 |
|
51,902,903 |
|
|
|
|
|
|
Non-current liabilities |
8,389,072 |
|
7,879,133 |
|
Long term borrowings-net of current maturity |
1,963,675 |
|
1,757,971 |
|
Liability for gratuity, pension and WPPF |
3,863,051 |
|
3,546,580 |
|
Deferred tax liability |
2,562,346 |
|
2,574,582 |
|
|
|
|
|
|
Current liabilities |
11,119,247 |
|
9,561,987 |
|
Short term borrowings |
4,386,777 |
|
2,996,660 |
|
Long term borrowings-current maturity |
1,091,878 |
|
1,270,800 |
|
Trade and other payables |
3,324,104 |
|
3,671,372 |
|
Accrued expenses |
1,272,457 |
|
1,106,665 |
|
Dividend payable |
311,718 |
|
87,223 |
|
Income tax payable |
732,313 |
|
429,267 |
|
TOTAL LIABILITIES |
19,508,319 |
|
17,441,120 |
|
TOTAL EQUITY AND LIABILITIES |
74,854,843 |
|
69,344,023 |
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July 2024-March 2025
|
|
|
|
|
|
|
|
Taka '000
|
|
|
|
|
|
|
|
|
|
|
|
July 2024 - March 2025 |
|
July 2023 - March 2024 |
|
January - March 2025 |
|
January - March 2024 |
|
|
|
|
|
|
|
|
|
|
Net revenue |
36,621,960 |
|
33,050,916 |
|
12,608,553 |
|
10,987,338 |
|
Cost of goods sold |
(19,822,775) |
|
(18,448,115) |
|
(6,787,928) |
|
(6,184,085) |
|
|
|
|
|
|
|
|
|
|
Gross profit |
16,799,185 |
|
14,602,801 |
|
5,820,625 |
|
4,803,253 |
|
|
|
|
|
|
|
|
|
|
Operating expenses |
(9,288,133) |
|
(8,083,749) |
|
(3,397,217) |
|
(2,826,393) |
|
General and administrative expenses |
(1,026,632) |
|
(985,625) |
|
(338,255) |
|
(333,191) |
|
Selling, marketing and distribution expenses |
(8,261,501) |
|
(7,098,124) |
|
(3,058,962) |
|
(2,493,202) |
|
Profit from operations |
7,511,052 |
|
6,519,052 |
|
2,423,408 |
|
1,976,860 |
|
|
|
|
|
|
|
|
|
|
Other income |
481,900 |
|
246,324 |
|
255,345 |
|
114,876 |
|
Finance cost |
(802,608) |
|
(860,732) |
|
(314,630) |
|
(289,030) |
|
Profit before tax and WPPF |
7,190,344 |
|
5,904,644 |
|
2,364,123 |
|
1,802,706 |
|
Contribution to WPPF |
(351,606) |
|
(286,781) |
|
(116,347) |
|
(86,901) |
|
Profit before tax |
6,838,738 |
|
5,617,863 |
|
2,247,776 |
|
1,715,805 |
|
Income tax expenses |
(1,577,731) |
|
(1,243,136) |
|
(521,780) |
|
(349,247) |
|
Current tax |
(1,580,974) |
|
(1,293,986) |
|
(517,572) |
|
(369,934) |
|
Deferred tax |
3,243 |
|
50,850 |
|
(4,208) |
|
20,687 |
|
Profit after tax |
5,261,007 |
|
4,374,727 |
|
1,725,996 |
|
1,366,558 |
|
|
|
|
|
|
|
|
|
|
Profit/(loss) attributable to: |
|
|
|
|
|
|
|
|
Owners of the Company |
5,231,738 |
|
4,350,901 |
|
1,721,356 |
|
1,364,518 |
|
Non-controlling interest |
29,269 |
|
23,826 |
|
4,640 |
|
2,040 |
|
|
5,261,007 |
|
4,374,727 |
|
1,725,996 |
|
1,366,558 |
|
Other comprehensive income/(loss) |
1 |
|
- |
|
- |
|
- |
|
Total comprehensive income |
5,261,008 |
|
4,374,727 |
|
1,725,996 |
|
1,366,558 |
|
|
|
|
|
|
|
|
|
|
Total comprehensive income attributable to: |
|
|
|
|
|
|
|
|
Owners of the Company |
5,231,739 |
|
4,350,901 |
|
1,721,356 |
|
1,364,518 |
|
Non-controlling interest |
29,269 |
|
23,826 |
|
4,640 |
|
2,040 |
|
|
5,261,008 |
|
4,374,727 |
|
1,725,996 |
|
1,366,558 |
|
|
|
|
|
|
|
|
|
|
Earnings per share (EPS) |
11.73 |
|
9.75 |
|
3.86 |
|
3.06 |
|
|
|
|
|
|
|
|
|
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July 2024-March 2025
For the period July 2024-March 2025
Taka '000
|
|
Share capital |
Share premium |
Excess of issue price over Face value of GDRs |
Capital reserve on merger |
Revaluation surplus |
Unrealized gain/(loss) |
Retained earnings |
Equity attributable to owners of the company |
Non-controlling interest |
Total equity |
|
Balance as on July 01, 2024 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,137,306 |
18,148 |
35,079,327 |
47,949,965 |
3,952,938 |
51,902,903 |
|
Total comprehensive income: |
|
|
||||||||
|
Profit/(loss) for the period |
- |
- |
- |
- |
- |
- |
5,231,738 |
5,231,738 |
29,269 |
5,261,007 |
|
Other comprehensive income/(loss) |
- |
- |
- |
- |
- |
1 |
- |
1 |
- |
1 |
|
Transactions with the shareholders: |
||||||||||
|
Cash dividend |
- |
- |
- |
- |
- |
- |
(1,784,448) |
(1,784,448) |
(33,687) |
(1,818,135) |
|
Others: |
||||||||||
|
Adjustment for depreciation on revalued assets |
- |
- |
- |
- |
(3,325) |
- |
3,325 |
- |
- |
- |
|
Adjustment for deferred tax on revalued assets |
- |
- |
- |
- |
748 |
- |
- |
748 |
- |
748 |
|
Balance as on March 31, 2025 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,134,729 |
18,149 |
38,529,942 |
51,398,004 |
3,948,520 |
55,346,524 |
|
Net asset value (NAV) per share |
|
|
|
|
|
|
Tk. |
115.21 |
|
|
For the period July 2023-March 2024
|
|
Share capital |
Share premium |
Excess of issue price over Face value of GDRs |
Capital reserve on merger |
Revaluation surplus |
Unrealized gain/(loss) |
Retained earnings |
Equity attributable to owners of the company |
Non-controlling interest |
Total equity |
|
|
Balance as on July 01, 2023 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,141,178 |
18,148 |
30,806,194 |
43,680,704 |
3,938,962 |
47,619,666 |
|
|
Total comprehensive income: |
|
|
|||||||||
|
Profit/(loss) for the period |
- |
- |
- |
- |
- |
- |
4,350,901 |
4,350,901 |
23,826 |
4,374,727 |
|
|
Transactions with the shareholders: |
|||||||||||
|
Cash dividend |
- |
- |
- |
- |
- |
- |
(1,561,392) |
(1,561,392) |
(23,267) |
(1,584,659) |
|
|
Others: |
|||||||||||
|
Adjustment for depreciation on revalued assets |
- |
- |
- |
- |
(3,747) |
- |
3,747 |
- |
- |
- |
|
|
Adjustment for deferred tax on revalued assets |
- |
- |
- |
- |
843 |
- |
- |
843 |
- |
843 |
|
|
Balance as on March 31, 2024 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,138,274 |
18,148 |
33,599,450 |
46,471,056 |
3,939,521 |
50,410,577 |
|
|
Net asset value (NAV) per share |
|
|
|
|
|
|
Tk. |
104.17 |
|
|
|
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July 2024-March 2025
|
|
July 2024 - March 2025 |
|
Taka '000
July 2023 - March 2024 |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
|
Cash receipts from customers and others |
36,394,207 |
|
33,160,408 |
|
Cash paid to suppliers and employees |
(30,100,181) |
|
(24,573,460) |
|
Cash generated from operations |
6,294,026 |
|
8,586,948 |
|
|
|
|
|
|
Interest paid |
(769,431) |
|
(853,639) |
|
Interest received |
18,479 |
|
2,626 |
|
Income tax paid |
(1,322,242) |
|
(1,137,217) |
|
Net cash generated from operating activities |
4,220,832 |
|
6,598,718 |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Acquisition of property, plant and equipment |
(2,220,342) |
|
(1,372,788) |
|
Intangible assets |
(164,411) |
|
(205,266) |
|
Disposal of property, plant and equipment |
40,123 |
|
25,252 |
|
Dividend received |
975 |
|
1,143 |
|
Short term investment |
(700,000) |
|
(200,000) |
|
Net cash used in investing activities |
(3,043,655) |
|
(1,751,659) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
|
Net increase/(decrease) in long term borrowings |
47,161 |
|
(910,718) |
|
Net increase/(decrease) in short term borrowings |
1,390,117 |
|
(2,351,356) |
|
Dividend paid |
(1,593,640) |
|
(1,568,205) |
|
Net cash from/(used in) financing activities |
(156,362) |
|
(4,830,279) |
|
Increase/(decrease) in cash and cash equivalents |
1,020,815 |
|
16,780 |
|
Opening cash and cash equivalents |
854,106 |
|
1,135,686 |
|
Effect of exchange rate changes on cash and cash equivalents |
8,179 |
|
7,958 |
|
Closing cash and cash equivalents |
1,883,100 |
|
1,160,424 |
|
|
|
|
|
|
Net operating cash flows per share |
9.46 |
|
14.79 |
|
|
|
|
|